EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model

Wiktoria Bębenek iD, Arkadiusz Gajek iD, Agnieszka Marczak iD, Jan Malý, Jiří Smejkal, Małgorzata Statkiewicz, Natalia Rusetska, Magdalena Bryś iD, Aneta Rogalska iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26020834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Wiktoria Bębenek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) cells critically depend on PARP1 and CHK1 activation for survival. Combining the PARP inhibitor (PARPi) olaparib with a CHK1 inhibitor (MK-8776, CHK1i) produced a synergistic effect, reducing cell viability and inducing marked oxidative stress and DNA damage, particularly in the HepG2 cells. This dual treatment significantly increased apoptosis markers, including γH2AX and caspase-3/7 activity. Both HCC cell lines exhibited heightened sensitivity to the combined treatment. The effect of drugs on the expression of proliferation markers in an olaparib-resistant patient-derived xenograft (PDX) model of ovarian cancer was also investigated. Ovarian tumors displayed reduced tissue growth, as reflected by a drop in proliferation marker Ki-67 levels in response to PARPi combined with CHK1i. No changes were observed in corresponding liver tissues using Ki-67 and pCHK staining, which indicates the absence of metastases and a hepatotoxic effect. Thus, our results indicate that the dual inhibition of PARP and CHK1 may prove to be a promising therapeutic approach in the treatment of primary HCC as well as OC tumors without the risk of liver metastases, especially in patients with olaparib-resistant tumor profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesCarcinoma, HepatocellularLiver NeoplasmsOvarian NeoplasmsHumansFemaleAnimalsMiceDrug SynergismXenograft Model Antitumor AssaysPoly(ADP-ribose) Polymerase InhibitorsCell ProliferationApoptosisCell Line, TumorHep G2 CellsLiverDNA DamageCheckpoint Kinase 1

Stichwörter der Autor:innen

CHK1 inhibitorliver cancermetastasisolaparibovarian cancerreplication stresstargeted therapy

Substanzen

olaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsCheckpoint Kinase 1

Autor:innen und Institutionen

  • Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.
  • Doctoral School of Exact and Natural Sciences, University of Lodz, Jana Matejki 21/23, 90-237 Lodz, Poland.
  • Faculty of Science, University of Jan Evangelista Purkyně in Ústí nad Labem, 400 96 Ustí nad Labem, Czech Republic.
  • Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland.
  • Department of Experimental Immunology, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland.
  • Department of Cytobiochemistry, Institute of Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.

ORCID-Profile: Wiktoria Bębenek, Arkadiusz Gajek, Agnieszka Marczak, Magdalena Bryś, Aneta Rogalska

Förderung

  • National Science Centre, Poland

Zitieren

APA

Bębenek, W., Gajek, A., Marczak, A., Malý, J., Smejkal, J., Statkiewicz, M., Rusetska, N., Bryś, M., & Rogalska, A. (2025). MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020834

Vancouver

Bębenek W, Gajek A, Marczak A, Malý J, Smejkal J, Statkiewicz M, et al. MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020834

BibTeX
@article{Bbenek2025,
  author = {Bębenek, Wiktoria and Gajek, Arkadiusz and Marczak, Agnieszka and Malý, Jan and Smejkal, Jiří and Statkiewicz, Małgorzata and Rusetska, Natalia and Bryś, Magdalena and Rogalska, Aneta},
  title = {MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26020834}
}
Kostenlos starten →